Bristol-Myers Squibb's Opdivo couldn't topple Nexavar in HCC — but will better safety profile win over physicians?
BARCELONA — Bristol-Myers Squibb’s Opdivo couldn’t quite beat Nexavar, the standard of care in hepatocellular carcinoma, in its Phase III head-to-head. But investigators are still hoping that it can play a role in the frontline setting of this disease.
Thomas Yau of the University of Hong Kong, who led the Checkmate-459 study, hit hard on Opdivo’s “clinically meaningful” advantages over the entrenched therapy, particularly in terms of side effects and quality of life.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
